文献速递淋巴瘤

原发与继发甲状腺淋巴瘤患者临床特征及预后比较

[Comparisons of clinical characteristics and prognosis between patients with primary and secondary thyroid lymphoma].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2019-01-01

回顾性分析2002年1月至2018年10月收治的46例甲状腺淋巴瘤患者(PTL 19例,STL 27例)。两组均以弥漫大B细胞淋巴瘤为主要病理亚型;甲状腺肿大在PTL组更常见。PTL组与STL组5年总生存率分别为(87.4±8.4)%和(70.0±13.1)%(P=0.433)。IPI评分3~5分、血清IL-8升高为B细胞甲状腺淋巴瘤的不良预后因素。

要点

  • PTL与STL均以弥漫大B细胞淋巴瘤为主要病理亚型。
  • 甲状腺肿大在PTL组发生率100.0%(19/19),STL组29.6%(8/27)(P<0.001)。
  • IPI评分3~5分、血清IL-8升高对B细胞甲状腺淋巴瘤5年OS率有影响(P=0.040,P=0.022)。

核心结论

  • PTL和STL均以弥漫大B细胞淋巴瘤为主要病理亚型,甲状腺肿大在PTL中更多见。
  • IPI评分3~5分、血清IL-8升高为B细胞甲状腺淋巴瘤的不良预后因素。

研究设计与样本

  • 回顾性分析2002年1月至2018年10月收治的46例甲状腺淋巴瘤患者(PTL 19例,STL 27例)的病例资料。

主要发现

  • PTL组男4例、女15例,中位发病年龄57(28~82)岁;STL组男10例、女17例,中位年龄61(32~83)岁。
  • PTL、STL组均以弥漫大B细胞淋巴瘤为主要病理亚型,分别为14例(73.7%)、20例(74.1%)。
  • 甲状腺肿大在PTL组、STL组的发生率分别为100.0%(19/19)、29.6%(8/27)(P<0.001)。
  • 甲状腺球蛋白抗体/甲状腺过氧化物酶抗体升高在PTL组、STL组的发生率分别为81.3%(13/16)、43.8%(7/16)(P=0.028)。
  • PTL组、STL组Ann Arbor分期Ⅲ/Ⅳ期患者分别为2例(10.5%)、21例(77.8%)(P<0.001);血β2微球蛋白升高患者分别为1例(7.1%)、9例(47.4%)(P=0.013);IPI评分3~5分患者分别为1例(5.3%)、16例(59.3%)(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To compare clinical characteristics and prognosis between patients with primary (PTL) and secondary thyroid lymphoma (STL) . Methods: A retrospective analysis was performed on 46 patients with thyroid lymphoma (PTL 19, STL 27) from January 2002 to October 2018. Results: ①PTL group included 4 males and 15 females, with a median age of 57 years. The STL group included 10 males and 17 females, with a median age of 61 years. Diffuse large B-cell lymphoma (DLBCL) was the main pathological subtype in both PTL and STL groups, with 14 cases (73.7%) and 20 cases (74.1%) respectively. In terms of clinical manifestations, goiter was the most common symptom in PTL patients 100.0% (19/19) , while 29.6% (8/27) STL had goiter (P<0.001) . The incidences of increased thyroglobulin antibody (TRAb) /thyroid peroxidase antibody (TPO) were 81.3% (13/16) in PTL group and 43.8% (7/16) in STL group (P=0.028) respectively. Concerning the clinical features of patients, only two PTL patients (10.5%) with advanced Ann Arbor stage (Ⅲ/Ⅳ) , while 21 (77.8%) STL experienced advanced Ann Arbor stage (P<0.001) . Elevated serum β(2)-MG were appeared in 1 (7.1%) PTL and 9 (47.4%) STL patients (P=0.013) , and advanced IPI score (3-5) was more common in STL than PTL (59.3% vs 5.3%, P<0.001) . ②Among the 17 PTL patients who received treatments, 15 (88.2%) achieved remission; as for STL patients received treatments, 23/25 (92.0%) were in remission. The 5-year overall survival (OS) rates of PTL (n=17) and STL groups (n=25) were (87.4±8.4) % and (70.0±13.1) % (P=0.433) respectively. ③The 5-year OS rate in 41 patients with B-cell thyroid lymphoma was (81.1±7.5) %. Univariate analysis showed that IPI score of 3-5 (P=0.040) and high level of serum IL-8 (P=0.022) were significantly associated with poor outcome. Conclusion: DLBCL was the most common subtype in both PTL and STL, and goiter was the major symptom in PTL. IPI score of 3-5 and high level of serum IL-8 were unfavorable prognostic factors for patients with B-cell thyroid lymphoma. 目的: 比较原发甲状腺淋巴瘤(PTL)、继发甲状腺淋巴瘤(STL)的临床特征和疗效。 方法: 回顾性分析2002年1月至2018年10月收治的46例甲状腺淋巴瘤患者(PTL 19例,STL 27例)的病例资料。 结果: ①PTL组男4例,女15例,中位发病年龄57(28~82)岁;STL组男10例,女17例,中位年龄61(32~83)岁;PTL、STL组均以弥漫大B细胞淋巴瘤(DLBCL)为主要病理亚型,分别为14例(73.7%)、20例(74.1%);甲状腺肿大在PTL组、STL组的发生率分别为100.0%(19/19)、29.6%(8/27)(P<0.001);甲状腺球蛋白抗体(TRAb)/甲状腺过氧化物酶抗体(TPO)升高在PTL组、STL组的发生率分别为81.3%(13/16)、43.8%(7/16)(P=0.028);PTL组、STL组Ann Arbor分期Ⅲ/Ⅳ期患者分别为2例(10.5%)、21例(77.8%)(P<0.001),血β(2)微球蛋白升高患者分别为1例(7.1%)、9例(47.4%)(P=0.013),IPI评分3~5分患者分别为1例(5.3%)、16例(59.3%)(P<0.001)。②17例PTL患者接受治疗,15例(88.2%)获得缓解;25例STL患者接受治疗,23例(92.0%)获得缓解。③PTL组(17例)、STL组(25例)5年总生存(OS)率分别为(87.4±8.4)%、(70.0±13.1)%(P=0.433)。④B细胞甲状腺淋巴瘤患者(41例)的5年OS率为(81.1±7.5)%,IPI评分3~5分、血清IL-8升高对B细胞甲状腺淋巴瘤患者5年OS率有影响(P=0.040,P=0.022)。 结论: PTL和STL均以DLBCL为主要病理亚型,甲状腺肿大在PTL中更多见。IPI评分3~5分、血清IL-8升高为B细胞甲状腺淋巴瘤的不良预后因素。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Sun R, Shi Q, Shen R, et al. [Comparisons of clinical characteristics and prognosis between patients with primary and secondary thyroid lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 32397019. doi:10.3760/cma.j.issn.0253-2727.2019.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。